Yan Liang's research while affiliated with Beijing Medical University and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (9)
Remimazolam is a new ultra-short-acting benzodiazepine used to induce and maintain anesthesia and procedural sedation. Its compound structure is similar to midazolam's. Midazolam metabolism might be affected by vitamin D receptor (VDR), cytochrome P450 3A, and cytochrome P450 oxidoreductase genetic polymorphisms. This study investigated the effects...
Purpose:
The aim of the present study was to evaluate the safety, pharmacokinetic (PK) and pharmacodynamic (PD) properties of remimazolam besylate following single ascending dose (SAD) and continuous infusion in healthy Chinese volunteers.
Methods:
This was a randomized phase I study conducted in two parts. Part I was a double-blind, placebo- an...
- [...]
Background:
Hemoporfin is a porphyrin-based photosensitizer and has been used for photodynamic therapy of port wine stain birthmarks in China. This study assessed the pharmacokinetics and cutaneous photosensitization of Hemoporfin in healthy volunteers.
Methods:
Sixteen healthy subjects received a single intravenous infusion injection of Hemopor...
Aim: Evaluate steady-state pharmacokinetics and potential interactions between select statins and evacetrapib. Patients & methods: This open-label, two-part study included 62 healthy native Chinese subjects. Part 1 evaluated pharmacokinetics and pharmacodynamics of evacetrapib after 1 or 14 once-daily doses. Part 2 evaluated pharmacokinetics and ph...
MicroRNA-21 (miRNA-21) has recently been shown to be a promising prognostic tumor biomarker. However, few studies have not supported this idea and have shown inconsistent data. Thus, we conducted a meta-analysis to elucidate the predictive value of miRNA-21 in gliomas. The relevant studies were identified by performing online search in PubMed, EMBA...
Development and use of better medicine for children is a worldwide problem recently, especially in China. The current situation of drugs for children's renal diseases is far from well-understood now. This survey focused on drugs for pediatric renal diseases including immunosuppressants, corticosteroids, diuretics, anticoagulants, hypotensives and a...
The objectives of the present study were to investigate the pharmacokinetics (PK) of tacrine analogue octahydrogenacridine (OHA) succinate tablets in healthy Chinese subjects. A single-center, randomized, open-label, dose-escalation study was conducted in 42 healthy Chinese subjects. Part I of the study (n=30, 16 male and 14 female) evaluated the P...
To investigate the safety, tolerability and pharmacokinetics of intravenous hemoporfin, a novel photosensitive drug for the treatment of port-wine stain (PWS), in healthy Chinese volunteers following single-dose administration.
Thirty-six healthy Chinese subjects were enrolled. The subjects were administered hemoporfin (2.5, 5, 7.5 or 10 mg/kg) via...
Citations
... Remimazolam, one of the newest ultra-shortacting benzodiazepines, was developed by GSK [2] and was approved for use in China in July 2020 as a programmed sedative drug in adults. Similar to midazolam, remimazolam enhances γ-aminobutyric acid A (GABA A ) receptor activity to induce cell membrane hyperpolarization, thereby inhibiting neural activity via an increase in chloride influx [3]. With similar structural modifications to remifentanil, remimazolam is rapidly hydrolyzed to a pharmacologically inactive metabolite (CNS-7054) through the actions of non-specific tissue esterase activity [4]. ...
... The current study also showed that TLOC and ADS 50 were higher in the group receiving remimazolam than those in the group receiving propofol during remifentanilbased TIVA; this result is consistent with the results of previous studies. BIS and the Modified Observer Assessment of Alertness and Sedation (MOAA/S) scores have been used in previous comparative studies on the effects of remimazolam and propofol on the depth of anesthesia (17)(18)(19)(20). However, BIS was originally developed for monitoring the depth of propofol-based anesthesia, and there is a weak correlation between benzodiazepine-induced anesthetic depth and BIS (4). ...
... Among the various up-regulated miRs, miR-21 has been identified to be the most overexpressed miRNA in tumors, which may affect the development of cancer via different signaling cascades [94]. Overexpression of miR-21 was recognized as a prognostic and diagnostic biomarker in various cancers [95][96][97][98][99]. Furthermore, it was studied that high expression of miR-21 was correlated with low OS in glioma patients [100]. Our findings, which indicated a statistically significant correlation between the exomiR-21 and OS (HR = 2.655, P < 0.001), DFS/RFS/PFS (HR = 2.127, P < 0.001), and Lymph node metastasis (HR = 1.568, ...
... It has been well established that children are not small adults, but rather they are a distinct and heterogeneous patient group (Ivanovska et al., 2014;Wimmer et al., 2015). However, more than 50% of drug formulations are not age-appropriate for most of the pediatric groups (delMoral-Sanchez et al., 2020;Ye et al., 2013). Nowadays, formulation research and development in the pediatric area remains essential (Smyth et al., 2012). ...
... A pharmacokinetic study on HMME revealed that the plasma concentration reached its peak 20 min after administration and began to drop sharply 30 min post-administration [38] Therefore, the best time to irradiate is 10-30 min after the administration of HMME. Some patients tend to have large skin lesions; however, the area of the light source is generally limited (large spot: 10 9 10 cm; small spot: 5 9 5 cm). ...
